株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

B型血友病:パイプライン分析

Hemophilia B - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232835
出版日 ページ情報 英文 112 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
B型血友病:パイプライン分析 Hemophilia B - Pipeline Review, H2 2016
出版日: 2016年09月30日 ページ情報: 英文 112 Pages
概要

B型血友病は、血液凝固第IX因子の不足により生じる、遺伝性の出血疾患です。十分な量の第IX因子が無ければ、血液を凝固させて出血を効果的に塞ぐことができなくなります。主な症状として、関節内部での出血や、それに伴う関節痛・腫脹、紫斑、環状切除に伴う過剰出血、消化管・尿路からの出血、鼻血などがあります。主な治療法として、欠損した凝固因子の補充などがあります。

当レポートでは、世界各国でのB型血友病治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

B型血友病の概要

治療薬の開発

  • B型血友病向けパイプライン製品:概要
  • B型血友病向けパイプライン製品:比較分析

各企業で開発中のB型血友病治療薬

大学/研究機関で研究中のB型血友病治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

B型血友病治療薬:開発中の製品の一覧(企業別)

B型血友病治療薬:研究中の製品の一覧(大学/研究機関別)

B型血友病治療薬の開発に従事している企業

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics B.V.
  • AstraZeneca Plc
  • Baxalta Incorporated
  • Bayer AG
  • Biogen, Inc.
  • Catalyst Biosciences, Inc.
  • CSL Limited
  • Dimension Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • Novo Nordisk A/S
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Pharming Group N.V.
  • RegenxBio Inc.
  • rEVO Biologics, Inc.
  • Sangamo BioSciences, Inc.
  • Spark Therapeutics, Inc.
  • uniQure N.V.

B型血友病:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • albutrepenonacog alfa
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • ALN-AT3
  • AMT-060
  • AZ-10047130
  • BAX-335
  • BAY-1093884
  • CB-2679d
  • CB-813d
  • B型血友病向け細胞療法
  • 第IX凝固因子(遺伝子組み換え型)
  • 第IX凝固因子(遺伝子組み換え型)
  • 第IX凝固因子FC(遺伝子組み換え型), Fc 融合タンパク質
  • 第VIIa凝固因子 (遺伝子組み換え型)
  • concizumab
  • CSL-689
  • DTX-101
  • B型血友病向け遺伝子療法
  • B型血友病向け第IX因子活性化用遺伝子療法
  • B型血友病向け第IX因子活性化用遺伝子療法
  • MOD-5014
  • MOD-9017
  • nonacog beta pegol
  • PF-06741086
  • SB-FIX
  • SPK-FIX
  • SVF-VIIa

B型血友病治療薬:パイプライン製品の最新動向

B型血友病治療薬:開発が休止状態の製品

B型血友病治療薬:開発が中止された製品

B型血友病関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8522IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H2 2016, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 6, 6, 1, 6 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Hemophilia B.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hemophilia B Overview
  • Therapeutics Development
    • Pipeline Products for Hemophilia B - Overview
    • Pipeline Products for Hemophilia B - Comparative Analysis
  • Hemophilia B - Therapeutics under Development by Companies
  • Hemophilia B - Therapeutics under Investigation by Universities/Institutes
  • Hemophilia B - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hemophilia B - Products under Development by Companies
  • Hemophilia B - Products under Investigation by Universities/Institutes
  • Hemophilia B - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals, Inc.
    • Amarna Therapeutics B.V.
    • Bayer AG
    • Biogen Inc
    • Catalyst Biosciences, Inc.
    • China Biologic Products, Inc.
    • CSL Limited
    • Dimension Therapeutics, Inc.
    • Green Cross Corporation
    • MolMed S.p.A.
    • Novo Nordisk A/S
    • OPKO Biologics Ltd
    • Pfizer Inc.
    • Pharming Group N.V.
    • RegenxBio Inc.
    • rEVO Biologics, Inc.
    • Sangamo BioSciences, Inc.
    • Shire Plc
    • Spark Therapeutics, Inc.
    • UniQure N.V.
  • Hemophilia B - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AMT-060 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAX-335 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1093884 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-2679d - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor IX (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor IX (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor IX (recombinant), albumin fusion protein - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor IX (recombinant), pegylated - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • coagulation factor VIIa (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • concizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-689 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DTX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fitusiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LR-769 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • marzeptacog alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-1113A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOD-5014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06741086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Factor IX Replacement for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-FIX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPK-9001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SVF-VIIa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hemophilia B - Dormant Projects
  • Hemophilia B - Discontinued Products
  • Hemophilia B - Product Development Milestones
    • Featured News & Press Releases
      • Sep 26, 2016: Alprolix obtains reimbursement across the United Kingdom
      • Sep 07, 2016: Catalyst Biosciences to Focus on Improved Factor IX Clinical Hemostasis Program
      • Sep 06, 2016: Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing
      • Jul 26, 2016: CSL Behring Presents Phase III Data for IDELVION for Hemophilia B at the World Federation of Hemophilia 2016 World Congress
      • Jul 25, 2016: Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders
      • Jul 25, 2016: Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia 2016 World Congress
      • Jul 19, 2016: CSL Behring to Present New Data for IDELVION at the World Federation of Hemophilia 2016 World Congress
      • Jul 18, 2016: Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data on ALPROLIX at World Federation of Hemophilia 2016 World Congress
      • Jun 06, 2016: Sobi: First Alprolix sales in the EU
      • May 24, 2016: Catalyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst Next-Generation Factor VIIa Product CB 813d
      • May 16, 2016: Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of hemophilia B
      • May 13, 2016: Alprolix (rFIXFc) approved in the EU for the treatment of hemophilia B
      • May 12, 2016: IDELVION (rFIX-FP) - European Commission Approval
      • May 11, 2016: CSL Behring's Innovative Therapy for Hemophilia B Patients, IDELVION, Receives 7 Years of Marketing Exclusivity from the U.S. Food and Drug Administration
      • May 11, 2016: European Commission Approves IDELVION --CSL Behring Novel Hemophilia B Treatment with Up to 14-day Dosing Intervals
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hemophilia B, H2 2016
  • Number of Products under Development for Hemophilia B - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hemophilia B - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
  • Hemophilia B - Pipeline by Amarna Therapeutics B.V., H2 2016
  • Hemophilia B - Pipeline by Bayer AG, H2 2016
  • Hemophilia B - Pipeline by Biogen Inc, H2 2016
  • Hemophilia B - Pipeline by Catalyst Biosciences, Inc., H2 2016
  • Hemophilia B - Pipeline by China Biologic Products, Inc., H2 2016
  • Hemophilia B - Pipeline by CSL Limited, H2 2016
  • Hemophilia B - Pipeline by Dimension Therapeutics, Inc., H2 2016
  • Hemophilia B - Pipeline by Green Cross Corporation, H2 2016
  • Hemophilia B - Pipeline by MolMed S.p.A., H2 2016
  • Hemophilia B - Pipeline by Novo Nordisk A/S, H2 2016
  • Hemophilia B - Pipeline by OPKO Biologics Ltd, H2 2016
  • Hemophilia B - Pipeline by Pfizer Inc., H2 2016
  • Hemophilia B - Pipeline by Pharming Group N.V., H2 2016
  • Hemophilia B - Pipeline by RegenxBio Inc., H2 2016
  • Hemophilia B - Pipeline by rEVO Biologics, Inc., H2 2016
  • Hemophilia B - Pipeline by Sangamo BioSciences, Inc., H2 2016
  • Hemophilia B - Pipeline by Shire Plc, H2 2016
  • Hemophilia B - Pipeline by Spark Therapeutics, Inc., H2 2016
  • Hemophilia B - Pipeline by UniQure N.V., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hemophilia B - Dormant Projects, H2 2016
  • Hemophilia B - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hemophilia B, H2 2016
  • Number of Products under Development for Hemophilia B - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top